CAL
EVFM

Capital Analysts LLC’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

Capital Analysts LLC’s Portfolio EVFM Stock Details EVFM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-533
Closed -$14K – 1116
2021
Q1 		$14K Buy
+533
New +$24.2K ﹤0.01% 757

Other funds holding EVFM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FWSM
First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return

Capital Analysts LLC's EVFM Position: Q2 2021 in Review

Capital Analysts LLC sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q2 2021, closing a stake of 533 shares — an estimated $14K sold.

Capital Analysts LLC first reported a position in EVFM in Q1 2021 and held it in 1 quarter. The position peaked at $14K in Q1 2021. 81 funds tracked by Wall St. Rank hold EVFM as of Q2 2021.

  • Capital Analysts LLC reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Capital Analysts LLC sold 533 Evofem Biosciences, Inc. Common Stock shares in Q2 2021, an estimated $14K.
  • Capital Analysts LLC first reported a position in Evofem Biosciences, Inc. Common Stock in Q1 2021 and held it in 1 quarter.
  • Capital Analysts LLC's Evofem Biosciences, Inc. Common Stock position peaked at $14K in Q1 2021.
  • 81 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q2 2021.

Based on Capital Analysts LLC's 13F filing for Q2 2021, filed 5 Aug 2021.